Tourette Syndrome Clinical Trial
Official title:
Evaluation of Density and Pattern of Distribution of GABA A Receptors in Brain of Patients With Tourette's Syndrome Studied With PET Using [11C] Flumazenil
This study will investigate how the brain generates tics in patients with Tourette's syndrome
and which areas of the brain are primarily affected. Tourette's syndrome is a
neuropsychiatric disorder characterized by motor and vocal tics, and is associated with
behavioral and emotional disturbances, including symptoms of attention deficit hyperactivity
disorder and obsessive-compulsive disorder. This study will examine whether tic generation is
related to changes in brain cell receptors for a chemical messenger called gamma-aminobutyric
acid (GABA).
Healthy normal volunteers and patients with Tourette's syndrome between 21 and 65 years of
age may be eligible for this study. Candidates will be screened with a medical history and
physical and neurological examinations.
Participants will undergo positron emission tomography (PET) scanning to measure brain blood
flow. For this procedure, the subject receives an injection of H215O, a radioactive substance
similar to water. A special camera detects the radiation emitted by the H215O, allowing
measurement of the blood flow. Subjects will receive up to five injections of H215O during
the scanning. They will also be injected with another radioactive chemical, (11C) flumazenil,
which binds to GABA receptors, to measure the density and distribution of these receptors.
This will reveal which areas of the brain in patients with Tourette's syndrome have abnormal
binding of flumazenil compared with the brains of healthy control subjects.
During the PET procedure, the subject lies on a table in the PET scanner. A small catheter
(plastic tube) is placed in an arm vein for injecting the radioactive tracers, and a mask is
placed on the face to help keep the head still during scanning. The mask has large openings
for eyes, nose and mouth, so that it does not interfere with talking or breathing. The entire
test takes about 3 hours.
On a separate day, participants will also undergo magnetic resonance imaging (MRI), a
diagnostic test that uses a magnetic field and radio waves to produce images of the brain.
For this procedure, the subject lies still on a stretcher that is moved into the scanner (a
narrow cylinder containing the magnet). Earplugs are worn to muffle loud noises caused by
electrical switching of radio frequency circuits used in the scanning process. The scan lasts
about 45 to 60 minutes.
The purpose of this study is to determine if symptoms of Tourette's syndrome are due to
dysfunction of GABA-ergic neurons causing disinhibition originating in basal ganglia, and
involving thalamus, frontal and prefrontal cortices and contributing to tic generation.
The major inhibitory neurotransmitter in central nervous system is gamma-aminobutyric acid
(GABA), which acts mainly through the GABA A receptors. Pathological processes involving
GABA-ergic neurons cause alterations in the density of GABA A receptors of the targeted
neurons. These changes can be visualized and measured with Positron Emission Tomography using
as a radioactive ligand [11C] flumazenil. We will examine changes in the density and
distribution of GABA A receptors in 17 adult patients with a DSM-IV-TR (American Psychiatric
Association 2000) diagnosis of a tic disorder and 17 control subjects. This study should
provide new information concerning localization and degree of dysfunction of GABA-ergic
neurons in areas involved in Tourette's syndrome, which, in turn, might open new
possibilities in pharmacological treatment of this disorder.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04851678 -
Longitudinal Impact of Stressors in Adults With Tourette Syndrome
|
||
| Completed |
NCT02605902 -
Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders
|
N/A | |
| Completed |
NCT04007913 -
Incorporating teleCBIT Into a Hospital-Based Tic Program
|
N/A | |
| Completed |
NCT02900144 -
Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)
|
N/A | |
| Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
| Completed |
NCT02256475 -
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
|
Phase 1 | |
| Completed |
NCT01329198 -
Brain Stimulation for the Treatment of Tourette Syndrome
|
N/A | |
| Terminated |
NCT00952601 -
Pilot Study of the Modified Atkins Diet for Tourette Syndrome
|
Phase 1 | |
| Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
| Completed |
NCT00206323 -
A Randomized, Placebo-controlled, Tourette Syndrome Study.
|
Phase 3 | |
| Completed |
NCT00004376 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
|
Phase 3 | |
| Completed |
NCT04498364 -
Extinction Learning in Adults With Tourette Syndrome
|
N/A | |
| Completed |
NCT00755339 -
Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
|
||
| Completed |
NCT03325010 -
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
| Completed |
NCT01719523 -
Open-Trial of EPI-743 for Adults With Tourette Syndrome
|
Phase 1 | |
| Completed |
NCT01702077 -
Neurofeedback for Tourette Syndrome
|
N/A | |
| Completed |
NCT00231985 -
Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
|
Phase 2 | |
| Completed |
NCT00206336 -
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
|
Phase 3 | |
| Terminated |
NCT03732534 -
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
|
Phase 2 |